Vikram Paroth's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q2 2024
Question
Vikram Paroth of Morgan Stanley asked about the timeline for KT474 indication expansion beyond HS and AD, and also inquired about the indication selection strategy for the TIC2 program based on initial Phase 1 data.
Answer
President and CEO Nello Manalfi noted broad potential for KT474 in areas like respiratory and GI, but stated Sanofi would determine the timing for expansion. For TIC2, he highlighted its potential to block multiple pathways (IL-23, IL-12, type 1 interferon), with the Phase 1 goal being to demonstrate this differentiated mechanism to inform future indication choices like IBD and psoriasis.